RT Journal Article
SR Electronic
T1 Mobile health adherence for the detection of recurrent recent-onset atrial fibrillation
JF Heart
JO Heart
FD BMJ Publishing Group Ltd and British Cardiovascular Society
SP heartjnl-2022-321346
DO 10.1136/heartjnl-2022-321346
A1 Rachel M J van der Velden
A1 Nikki A H A Pluymaekers
A1 Elton A M P Dudink
A1 Justin G L M Luermans
A1 Joan G Meeder
A1 Wilfred F Heesen
A1 Timo Lenderink
A1 Jos W M G Widdershoven
A1 Jeroen J J Bucx
A1 Michiel Rienstra
A1 Otto Kamp
A1 Jurren M van Opstal
A1 Charles J H J Kirchhof
A1 Vincent F van Dijk
A1 Henk P Swart
A1 Marco Alings
A1 Isabelle C Van Gelder
A1 Harry J G M Crijns
A1 Dominik Linz
YR 2022
UL http://heart.bmj.com/content/early/2022/08/29/heartjnl-2022-321346.abstract
AB Objective The Rate Control versus Electrical Cardioversion Trial 7–Acute Cardioversion versus Wait and See trial compared early to delayed cardioversion for patients with recent-onset symptomatic atrial fibrillation (AF). This study aims to evaluate the adherence to a 4-week mobile health (mHealth) prescription to detect AF recurrences after an emergency department visit.Methods After the emergency department visit, the 437 included patients, irrespective of randomisation arm (early or delayed cardioversion), were asked to record heart rate and rhythm for 1 min three times daily and in case of symptoms by an electrocardiography-based handheld device for 4 weeks (if available). Adherence was appraised as number of performed measurements per number of recordings asked from the patient and was evaluated for longitudinal adherence consistency. All patients who used the handheld device were included in this subanalysis.Results 335 patients (58% males; median age 67 (IQR 11) years) were included. The median overall adherence of all patients was 83.3% (IQR 29.9%). The median number of monitoring days was 27 out of 27 (IQR 5), whereas the median number of full monitoring days was 16 out of 27 (IQR 14). Higher age and a previous paroxysm of AF were identified as multivariable adjusted factors associated with adherence.Conclusions In this randomised trial, a 4-week mHealth prescription to monitor for AF recurrences after an emergency department visit for recent-onset AF was feasible with 85.7% of patients consistently using the device with at least one measurement per day. Older patients were more adherent.Trial registration number NCT02248753.Data are available on reasonable request. Data will be made available after an application atcarim-office@maastrichtuniversity.nl.